Journal of Cystic Fibrosis

Article	Citations
Editorial Board	181
Regarding the article entitled “Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis”	97
132 Respiratory symptom changes during menstrual cycles in women with cystic fibrosis	81
126 Change in pulmonary function after introduction of elexacaftor/tezacaftor/ivacaftor: Results from the national cystic fibrosis cohort in Denmark	67
163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label ex	65
230 Increasing the number of completed colonoscopies among eligible adults with cystic fibrosis	60
300 Higher Edinburgh Postnatal Depression Scale scores in caregivers of infants with cystic fibrosis	60
228 Hold the mayo on the elexacaftor/tezacaftor/ivacaftor special! A single-center experience	59
223 Divergent liver enzyme tests over the first year of elexacaftor/tezacaftor/ivacaftor therapy	58
164 Tolerance of ETD001, a long-acting inhaled epithelial sodium channel blocker, in humans	58
191 Cystic fibrosis transmembrane conductance regulator potentiator (ivacaftor) has minimal effects on gut microbiome composition in people with cystic fibrosis and gating mutations	54
145 Prescription of elexacaftor/tezacaftor/ ivacaftor in lung transplant recipients with cystic fibrosis	50
196 Liver function test abnormalities in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor	50
291 Development and validation of the Cystic Fibrosis Stress Questionnaire: A cystic fibrosis–specific measure of perceived stress	49
208 Fat-soluble vitamin level trends after elexacaftor/tezacaftor/ivacaftor therapy	49
205 Do we need a colorectal cancer screening program for patients with cystic fibrosis?	49
299 Parental stress, feeding style, and mealtime behaviors of children with cystic fibrosis	48
236 Screening for celiac disease in people with cystic fibrosis	48
424 Systems serology in cystic fibrosis: Anti-Pseudomonas immunoglobulin G1 responses and reduced lung function	46
256 Tobramycin pharmacokinetic differences in patients after initiation of highly effective modulator therapy	45
284 “You're not alone”: Implementation and challenges of a virtual cystic fibrosis parent group	44
304 Using network learning models to facilitate best practices for successful conversations prompted from the daily care check-in	43
283 Expectations and experiences of adolescents with cystic fibrosis: Influence of elexacaftor/tezacaftor/ivacaftor on treatment adherence and identity	42
254 Patient perception of the impact of elexacaftor/tezacaftor/ivacaftor and the COVID-19 pandemic on physical and mental health	42
417 Resolvin D1 reduces cystic fibrosis lung disease and inflammation associated with mucus obstruction	39

305 Empowerment in adolescents and young adults with cystic fibrosis	39
257 Rapid health decline in young cystic fibrosis transmembrane conductance regulatorG551D ferrets after discontinuation of cystic fibrosis transmembrane conductance regulator modulator	38
189 Impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis	37
135 Electronic home monitoring of children with cystic fibrosis to detect and treat acute pulmonary exacerbations and its effect on 1-year FEV1 loss	37
150 Initiation of standardized care pathway for individuals with cystic fibrosis transmembrane conductance regulator–related metabolic syndrome at a large cystic fibrosis center	37
144 Computed tomography body composition and clinical outcomes after lung transplantation in cystic fibrosis	37
172 Treatment changes and outcomes in adults taking elexacaftor/tezacaftor/ivacaftor at two years: A single-center experience	34
131 Feasibility of telehealth spirometry for people with cystic fibrosis	34
143 Bronchoalveolar lavage proteome identifies pathways of disease that segregate lung transplant recipients with and without bronchiolitis obliterans syndrome	34
152 My patient has an unresolved CFTR genotype … what next?	32
232 Increase in weight-for-age and vegetable intake in young children with cystic fibrosis treated with lumacaftor/ivacaftor for 24 weeks	32
242 Palliative care needs in cystic fibrosis: Baseline data from the Improving Life with Cystic Fibrosis Multi-site Implementation Trial for Primary Palliative Care Intervention	32
Demographic factors associated with within-individual variability of lung function for adults with cystic fibrosis: A UK registry study	31
260 Cystic fibrosis transmembrane conductance regulator modulator–associated liver inflammation in pediatric cystic fibrosis	31
Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis	30
188 The microbial-binding lectin, intelectin-1, but not intelectin-2, is upregulated by airway infections and is altered in people with cystic fibrosis	29
242 Combined therapeutic strategies to favor repair and regeneration of airway epithelium in cystic fibrosis despite presence of bacterial infection	29
164 Comprehensive methods to assess pharmacokinetics and monitor for viral shedding, replication competence, and immunogenicity of BI 3720931 in the first-in-human Lenticlair 1 Phase I/II trial	28
311 Prime editing enables efficient, precise correction of CFTR F508del and functional rescue in human airway epithelial cells	28
Contents	28
382 Designing a novel cystic fibrosis genetic counseling telehealth model: a mixed-methods study informed by implementation science	28
287 Screening for translational readthrough of CFTR R1162X leads to the identification of mammalian target of rapamycin inhibitors for nonsense suppression	28
699 Rates of emerging non-pulmonary complications in adults with cystic fibrosis and in the general population	27
834 Airway clearance and antibiotic selection for pulmonary exacerbations in the STOP PEDS pilot study	27
142 Clinical outcomes after 2 years of treatment with elexacaftor/tezacaftor/ivacaftor in children aged 6 to −11 with cystic fibrosis—The RECOVER Study	27
526 Non-surgical management of urinary incontinence in women with cystic fibrosis	27
783 Health of the healthcare worker: understanding the role of physical activity among a CF care team	26
184 Bioengineered three-dimensional cystic fibrosis lung airway model for drug testing	26
383 Assessing cystic fibrosis regulatory modulators: a comprehensive retrospective analysis on patient subgroups and clinical outcomes	25
773 A quality improvement project to improve the evaluation of low bone density in people with cystic fibrosis	25
304 Assessing a novel dual-endonuclease system in restoring CFTR expression in cystic fibrosis humanized mouse and human airway models	25
497 Management strategies for hepatotoxicity associated with elexacaftor/tezacaftor/ivacaftor: results of a provider survey	25
694 Vitamin D deficiency, seasonal variation, and relationship with clinical parameters in children and adolescents with cystic fibrosis from Buenos Aires, Argentina	24
332 Systematic review of paired patient-derived tissue and clinical responses to CFTR modulators in people with CF highlights need for standardization in theratyping	24
667 Hypoglycemia during extended oral glucose tolerance test in a large cohort of youth and adults with cystic fibrosis	24
601 Impact of CFTR modulator therapy on acute pancreatitis frequency in children with acute recurrent or chronic pancreatitis: a report from INSPPIRE-2	24
648 Using the TriNetX international database of rare disease: GI manifestations in children and young adults with cystic fibrosis before and after the highly effective triple modulator therapy era	24
494 Pharmacokinetics of elexacaftor/tezacaftor/ivacaftor with concomitant rifabutin	24
635 Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF (STRONG-CF): a study protocol	23
103 Impact of limiting glucose on Staphylococcus aureus infections in the cystic fibrosis airway	23
827 The effect of telemonitoring in preventing lung function decline in cystic fibrosis	23
320 Gain-of-function CFTR mutation improves function of W1282X CFTR	22
646 Gastrostomy tubes after modulator therapy: practices at one cystic fibrosis center	22
702 Identification of geographically distinct regions of Mycobacterium abscessus acquisition of the dominant circulating clone and the nondominant circulating clone in people with cystic fibrosis	22
407 Neonatology knowledge of cystic fibrosis newborn screening algorithm updates	22
99 Development and validation of a deep neural network to predict antimicrobial resistance in people with cystic fibrosis using routinely collected electronic healthcare record data	22
260 RCT2100 rescue of cystic fibrosis (CF) transmembrane conductance regulator function in CF human bronchial epithelial cells and mucociliary clearance in CF ferrets	21
564 “How do you live the best life you can with this pain?” A qualitative study of the challenges of living with CF and pain in the modulator era	21
321 Epitranscriptional regulation of endothelial-to-mesenchymal transition in cystic fibrosis lung disease	21
15 Ex vivo pig lung as a new CF model for the study of Pseudomonas aeruginosa infection and phage therapy application	21

222 Inverse regulation of inflammasome and interferon mediators by human neutrophils adapted to the cystic fibrosis lung microenvironment	21
435 When quality improvement is not enough: a novel framework that pushes beyond plan-do-study-act to embrace “productive discomfort” and effect change	21
27 Standing up to the “bully”: Staphylococcus aureus can sustain long-term infection in the presence of Pseudomonas aeruginosa and may outcompete in the cystic fibrosis airway	21
739 A quality improvement initiative improves timeliness of sweat test completion after referral for positive newborn screen at a large single center	21
514 Real-word effectiveness of a Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis	21
632 Change in insulin secretion and sensitivity in people with cystic fibrosis and negative history for diabetes after 6 months of elexacaftor/tezacaftor/ivacaftor therapy	20
389 Lactic acid–producing bacteria levels are higher in CFTR-deficient colon crypt microbiota, and lactate potentiates clonogenicity and stem cell capacity in colonic organoids and cancer cells	20
519 Mental health assessment in young children initiating elexacaftor/tezacaftor/ivacaftor	20
597 Uncovering the knowledge gap: examination of cystic fibrosis knowledge in Canada	20
568 Implicit bias workshop increases bias literacy and acknowledgement of personal bias in psychosocial CF care team members	19
125 Improvement in abdominal symptoms (CFAbd-Score) and gut inflammation over 12 months of treatment with elexacaftor/tezacaftor/ivacaftor in children with CF aged 6 to 11—results from the RECOVER stu	19
710 Montana CF newborn screening quality improvement initiative	19
861 Comparing home spirometry with clinic spirometry in people with cystic fibrosis	19
20 Unraveling the pathogenicity of Mycobacterium abscessus in cystic fibrosis pulmonary epithelial cell and mouse models of respiratory infection	18
369 Characterization of the disease liability of rare CFTR variants	18
17 In vitro modeling of polymicrobial airway infections accurately represents gene expression of Pseudomonas aeruginosa in chronic cystic fibrosis infection	18
779 Transition: a multidisciplinary approach	18
679 Effect of hybrid closed loop insulin delivery on glycemic control in adolescents and adults with cystic fibrosis-related diabetes	18
566 Male sexual and reproductive health in cystic fibrosis: a concept mapping study	18
232 Mucoadhesive forces, microrheology, and vertical clearance of mucus against gravity	18
832 Long-term effects of elexacaftor/tezacaftor/ivacaftor therapy on airway and systemic inflammation in CF	17
851 Asthma biologic therapy and time to next cystic fibrosis pulmonary exacerbation	17
60 Pyochelin-mediated cefiderocol sensitization depends on the FptA transporter	17
89 Regulation and function of the fibrillar adhesin CdrA in Pseudomonas aeruginosa isolates that persist after initiation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis	17
706 Advanced CF Lung Disease (ACFLD) in the CFFPR: Incidence of ACFLD and Characteristics of the ACFLD Population	17
127 Elexacaftor/tezacaftor/ivacaftor therapy improves lung clearance index and MRI scores in children with cystic fibrosis and one or two F508del alleles	17
11 Ketogenesis enables disease tolerance during Pseudomonas aeruginosa pulmonary infection	17
558 Challenges faced by parents of children with cystic fibrosis in Ireland: The Irish Comparative Outcome Study of Cystic Fibrosis	17
108 Estimating the composition of the cystic fibrosis pulmonary microbiome	17
235 Differential regulation of immune function by highly effective CFTR modulators in THP-1-derived macrophages	16
588 Mind the hype: evaluating the mental and behavioral impacts of newstart CFTR modulators in children with CF	16
423 Does where you live matter? The impact of residency location on financial outcomes	16
683 Role of HbA1c in screening for CF-related diabetes—an adult and pediatric study	16
30 The de novo pyrimidine synthesis pathway regulates Pseudomonas aeruginosa infection in the cystic fibrosis lung	16
600 Changes in fecal pancreatic elastase in children with CF with 6 months of highly effective modulator therapy: Results from the BEGIN study	16
77 Tuning enantioselectivity of epoxide hydrolases by engineering the active-site cavity and substrate-entry tunnel	16
1 Pseudomonas aeruginosa-phage interactions are influenced by polymicrobial biofilms	16
286 Inhaled amphotericin shows good safety and tolerability in Phase 1 single-ascending-dose and multiple-ascending-dose studies in healthy subjects	16
262 Intratracheal administration of AAV2.5T-SP183-fCFTRΔR in combination with doxorubicin is able to correct the mucociliary clearance defect in cystic fibrosis model ferrets	16
582 Making new connections: an acceptance commitment therapy–informed telehealth group for teens with CF	16
637 Effects on vitamin A levels in children with cystic fibrosis after initiation of elexacaftor/tezacaftor/ivacaftor	15
535 CFTR-related disorders. Is there any indication for physiotherapy review?	15
444 Research Expansion to Advance the CF Therapeutic Pipeline for People with CF without Modulators	15
725 Insights from Cystic Fibrosis Foundation Patient Registry data on cancer in people with CF	15
300 Rescuing G542X by adenine base editing: a guide to restore function	15
529 Are adults with cystic fibrosis choosing to continue with airway clearance therapy in the era of highly effective gene modulator therapy?	15
490 What are the experiences of cystic fibrosis clinical nurse specialists? Are systemic practice ideas unknowingly incorporated when working with children and families?	15
230 Evaluation of immunofluorescence-4 inhibitor apremilast against acute Pseudomonas aeruginosa challenge in cystic fibrosis rats	15
718 Rates of longitudinal estimated glomerular filtration rate decline in participants in the Standardized Treatment of Pulmonary Exacerbations clinical trial	14
170 Elexacaftor/tezacaftor/ivacaftor induces a Th2 cytokine increase in cystic fibrosis sputum and results in a Th1 to Th2 class switch in airway inflammation	14
475 Impact of patient race and newborn screen status on pediatric primary care providers’ self-reported consideration of a CF diagnosis	14
317 Improving N1303K rescue by combining elexacaftor/tezacaftor/ivacaftor with β2 agonist formoterol	14
814 Screening for CF-associated hepatobiliary disease in children and adults	14
116 Exploring the diversity and function of the RTA1-like protein family in Aspergillus fumigatus	14
313 BEST4+ CFTR high expresser cells in normal rat are neuropods that sense and respond to luminal pH and are altered in dF508 CF intestine	14
271 Prime editing functionally corrects rare and common cystic fibrosis–causing mutations in patient-derived organoids and airway epithelia	14
239 Impact of DNA on the rheological properties of mucus	14
844 Feasibility and efficacy of remote symptom monitoring and automated treatment plans in children with CF	14
224 Role of electrogenic and electroneutral monocarboxylate transport in airway clearance	14
586 Description of a novel therapeutic support group for siblings of children with cystic fibrosis: Siblings Supporting Others and Achieving Resilience	14
539 Data harmonization: the next frontier in physiotherapy	13
824 Implementation of patient experience surveys to improve CF care: the ExPaParM-ACTION research study	13
338 Novel role for alpha-thalassemia x-linked intellectual disability syndrome in regulation of CFTR gene expression	13
835 The expanded French compassionate program for elexacaftor/tezacaftor/ivacaftor use in non-p.Phe508del people with cystic fibrosis	13
160 Nasal potential difference in young children is feasible: report from a national referral center	13
186 Characterization of ionocyte subtypes in cystic fibrosis ferret	13
279 Adeno-associated virus-1 or 6-Δ27-264 CFTR successfully ameliorated clinical symptoms in G551D ferrets	13
657 Performance of HbA1c for CFRD screening: analysis of U.S. Cystic Fibrosis Foundation Patient Registry Data	13
808 Implementation of physical therapy and exercise education in annual cystic fibrosis clinic	13
364 Characterization of the rare CFTR genotype c.1393-1G>A using intestinal organoids	13
135 Detection of nontuberculous mycobacteria abscessus and phage treatment response using volatile biomarkers	13
737 Patient characteristics in cystic fibrosis-related asthma	13
180 Development and application of a liquid chromatography–mass spectrometry method for monitoring CFTR modulators in biological fluids: a step forward in personalized CF treatment	13
281 A novel induced pluripotent stem cell–derived intestinal organoid protocol to assess CF therapies	13
365 Differential effects of (S)- and (R)-vanzacaftor on BKCa potentiation and CFTR correction	13
169 Stockholm Elexacaftor/Tezacaftor/Ivacaftor Task Force Study: cohort description and identification of subgroups	13
ECFS standards of care on CFTR-related disorders: Identification and care of the disorders	13
549 Screening for behavioral changes after elexacaftor/tezacaftor/ivacaftor initiation in children aged 2 to 5	13
209 Inositol-requiring enzyme 1β is a therapeutic target for cystic fibrosis airway muco-obstructive disease	13
512 Patient perceptions of mental health adverse effects from elexacaftor/tezacaftor/ivacaftor in a pediatric and adult CF center	13

Immune response of polarized cystic fibrosis airway epithelial cells infected with Influenza A virus	12
WS01.03 CFTR modulators impact antibiotic susceptibility of Pseudomonas aeruginosa and Staphylococcus aureus	12
WS05.03 Metabolomic impact of the restoration of CFTR activity in the respiratory epithelium	12
WS03.03 Qualitative analyses of the experiences of people with end-stage cystic fibrosis lung disease receiving ELX/TEZ/IVA	12
Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis	12
Forewarned is forearmed: The cardiovascular time bomb in Cystic Fibrosis	12
WS05.06 Novel high-throughput screening tool for monitoring CFTR levels and localisation in cytoplasm membrane with luminescent peptide tag	12
480 Weight stigma among healthcare professionals treating CF in North America	12
Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor	12
WS04.06 Neoplastic disease and treatment in cystic fibrosis (CF): a comprehensive single centre case series	12
5: Testosterone deficiency in men with cystic fibrosis: Understanding prevalence & association with clinical outcomes	12
WS11.02 Inconsistent IRT threshold values and CFTR panels in newborn screening for cystic fibrosis across the United States	11
44: Characterizing the COVID-19 pandemic among Canadians living with cystic fibrosis: A Canadian Cystic Fibrosis Registry study	11
WS12.06 Hypertonic saline triggers inflammatory responses in human macrophages	11
9: Pancreatic and islet vasculature are significantly diminished in CF donors – a potential contributor to insulin deficiency in CF	11
20: Performance of a statistical model in predicting cystic fibrosis–related diabetes (CFRD) utilizing genetic and non-genetic risk factors	11
40: Determining past contraceptive use among women with CF: Does survey administration method matter?	11
WS10.05 Physical fitness and habitual physical activity in adults with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?	11
WS11.01 Divergent diagnostic assessment of cystic fibrosis and related disorders: an analysis of paediatric cases categorisation by 50 international specialists	11
WS10.03 Impact of triple CFTR modulator therapy on urinary incontinence symptoms in adults with cystic fibrosis	11
13: Plasma acylcarnitines in adult cystic fibrosis and relationships with body composition and glucose tolerance	11
31: Epidemiology and CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian CF patients	11
21: Review of glycaemic control, nutritional status and lung function after initiation of flash glucose monitoring for patients with cystic fibrosis–related diabetes	11
WS11.03 Repeated sweat testing in children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)	11
WS11.04 Confirmatory genetic testing for all cystic fibrosis screen positive newborns: a 12-year analysis	11
WS08.05 Parenthood impacts short-term health outcomes in people with cystic fibrosis	11
11: A novel method to detect CF-related diabetes using changes in voice characteristics	11
WS07.05 Investigating the relationship between lung function decline and time to death or lung transplantation, accounting for geographical variability	11
414: Anaerobic microbiota facilitate Pseudomonas aeruginosa access to the airway epithelium in a novel co-culture model of colonization	10
397: Calpain-2 is increased in CF bronchoalveolar lavage fluid	10
212 Ivacaftor ameliorates acute but not chronic Pseudomonas aeruginosa infection in cystic fibrosis rats	10
75: Access to education and support for adults with cystic fibrosis by virtual support group with a focus on readiness for lung transplant	10
WS16.02 Base editing strategy to repair the CFTR 2789 + 5G > A splicing mutation	10
WS15.01 Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis of 3,100 patients	10
85: Antibiotic prescribing practice in pediatric cystic fibrosis patients at University of Rochester Medical Center: A quality improvement initiative	10
WS13.05 Mapping and tackling diversity in antibiotic resistance of sputum isolates in cystic fibrosis	10
420: Extracellular polysaccharides are metabolo-stimulatory ligands that favor Pseudomonas aeruginosa iron scavenging	10
412: Molecular mechanisms of cefiderocol resistance in Pseudomonas aeruginosa	10
403: Single-cell sequencing analyses of airway basal cell differentiation after lentiviral transduction	10
407: Pseudomonas aeruginosa-type IV pili-mediated chemotaxis enhances microbial competition	10
WS17.05 Elexacaftor/tezacaftor/ivacaftor (ETI) treatment in people with cystic fibrosis (pwCF) impacts airway progenitor cell function	10
WS16.03 LUNAR-CF: an mRNA replacement approach for cystic fibrosis lung disease	10
57: Secular drift in predictive accuracy of pulmonary exacerbations: A registry study	10
WS15.06 Fat-soluble vitamin status in F508del homozygous children with cystic fibrosis following commencement of lumacaftor/ivacaftor	10
209 Submerged differentiation of primary human airway cells facilitates functional studies and super resolution imaging	10
WS10.06 How representative are clinical trial cohorts of the general cystic fibrosis population? Implications for trial planning	10
WS11.02 Psychological wellbeing post-CFTR modulator therapy	10
208 Impact of corrector treatment on transcriptome analysis of CFBE41ocells cultured on cell culture inserts stably expressing F508del-mutant CFTR	10
68: Improving timeliness of CF diagnosis following a positive CF newborn screen in Washington State	10
WS13.06 Development of antibiotic resistance reveals diverse evolutionary pathways to face the complex and dynamic environment of a long-term treated patient	10
WS13.03 Real-world relevancy of qPCR for early detection of Pseudomonas aeruginosa infection in people with cystic fibrosis (pwCF)	10
195 Sinonasal epithelial responses to long-term highly effective CFTR modulator therapy	10
203 Mucociliary clearance is impaired in small airways of cystic fibrosis pigs	10
422: Antibiotic collateral sensitivity networks can inform treatment strategies for Burkholderia multivorans infections	9
428: Mechanisms of chlorate toxicity and resistance in Pseudomonas aeruginosa	9
404 Sex differences in mental well-being in children and adults with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor	9
WS14.04 Pseudomonas aeruginosa infection drives complex host responses in a cystic fibrosis-derived airway model	9
WS17.03 An alternative mutation agnostic therapy for cystic fibrosis with oligonucleotide antisense	9
427: Investigating the role of Pseudomonas aeruginosa lipid A deacylase PagL in cystic fibrosis airway infection	9
402 Can it be done? Avoiding insurance issues in a new plan year	9
WS13.01 The cystic fibrosis Home Sputum-Induction Trial (CF-HomeSpIT - ISRCTN86523335) to evaluate home sputum-induction and early morning saliva sampling in children with cystic fibrosis	9
438: Single-cell sequencing of healthy and CF basal lung epithelial cells reveals distinct transcriptional states in response to lipopolysaccharide and bacteriophage stimulation	9
418 Collaborative cystic fibrosis care: implementation of a pharmacist annual review	9
400 On-campus food pantry and home delivery program to aid with food insecurity in a combined adult and pediatric cystic fibrosis center	9
406 Social determinants of health screening and intervention within a large adult cystic fibrosis center	9
410 Multidisciplinary collaboration for transition readiness and planning	9
419 Impact of highly effective CFTR modulator therapy on use of antibiotics at a pediatric cystic fibrosis center	9
430: Tellurite agar identifies Staphylococcus aureus that elude detection in patients with cystic fibrosis	9
446: Novel detection of specific bacterial quorum-sensing molecules in saliva: Potential noninvasive biomarkers for pulmonary Pseudomonas aeruginosa in cystic fibrosis	8
453: Declining prevalence of epidemic strain of Pseudomonas aeruginosa in adults with cystic fibrosis: An 18-year single-center cohort study	8
424 Contemporary analysis in pancreatic enzyme use in the Nova Scotian cystic fibrosis population	8
467: Role of macrophages in CF lung infection and inflammation	8
P152 Development and validation of a personalised electronic patient-reported outcome measure to assess individual quality of life	8
P159 Modulator’s effectiveness evaluated by lung ultrasound	8
455: Aspergillus fumigatus persistence and infection in cystic fibrosis: Adaptation to hypoxia and in vivo HOG pathway mutation	8
WS18.05 Improved diagnosis of early aspergillus lung disease in cystic fibrosis (IDEAL) study design and first results	8
457: Achromobacter xylosoxidans as a cystic fibrosis–related opportunist	8
421 Evaluating adverse mental health event reports related to elexacaftortezacaftor-ivacaftor therapy in individuals with cystic fibrosis	8
471: Short RNAs in extracellular vesicles secreted by human airway epithelial cells increase antibiotic sensitivity of Pseudomonas aeruginosa	8
P156 Treatment with the CFTR modulator [HB1] elexacafor/tezacaftor/ivacaftor reduces immunological response to airway Aspergillus in people with cystic fibrosis	8
460: Prevalence of antimicrobial resistance mutations in Mycobacterium abscessus and associations with in vitro susceptibility testing	8
WS18.03 The effect of CFTR modulator therapy on the sputum proteome in cystic fibrosis	8
WS19.01 Non-adherence in the twilight zone: the complexity of complex medications	8
EPS1.01 Using lateral decubitus computed tomography (CT) to monitor structural lung disease in young children with cystic fibrosis	8
465: Intestinal function and transit relates to microbial dysbiosis in the CF gut	8
436 Documentation practices of cystic fibrosis pharmacists: an opportunity for discipline-wide quality improvement	8
614 Time between clinic visits of individuals with cystic fibrosis: patterns across the lifespan	8
P219 Otorhinolaryngologic, audiological and genetic findings in children with cystic fibrosis: a tertiary care experience	7
P213 Post-acute sequelae of COVID-19 in children with cystic fibrosis: a case-control study	7
P223 Transition programme as a quality improvement project: adaptation of the R.I.S.E. in a centre with limited resources – Marmara University experience	7
664 Sexual and reproductive health knowledge in cystic fibrosis patients: an evaluation and an intervention	7
653 Patient perspectives on clinic visits in the era of highly effective modulator therapy	7
P244 The impact of CFTR modulators on positive Pseudomonas aeruginosa (Pa) culture and antibiotic susceptibility in adults with cystic fibrosis	7
P212 Clinical and transcriptomic features of COVID-19 in cystic fibrosis: a prospective multi-centre study	7
650 Needs assessment: characterizing resident knowledge gaps in inpatient care of people with cystic fibrosis to inform a quality improvement educational intervention	7